SCHEMBL3017317

SCHEMBL3017317

COc1ccc(S(=O)(=O)C2CCN(c3nc(Cc4cc(C)ccc4C)cs3)CC2)cc1OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.39
HTT P42858 3/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 2/20 0.37
TSHR P16473 1/20 0.37
KDM4E B2RXH2 1/20 0.36
RAB9A P51151 3/20 0.36
NPC1 O15118 2/20 0.36
MAPT P10636 2/20 0.36
DNM1L O00429 1/20 0.34
SMPD3 Q9NY59 1/20 0.34
GBA1 P04062 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
HPGD P15428 1/20 0.34
CYP2C19 P33261 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
AR P10275 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3003521 0.90 TSHR (0.41) SMN1; SMN2HTTLMNAPOLBTSHR
SCHEMBL3011496 0.89 GBA1 (0.42) SMN1; SMN2HTTPOLBRAB9ANPC1
SCHEMBL3002775 0.89 KDM4E (0.40) SMN1; SMN2HTTLMNAPOLBTSHR
SCHEMBL3013286 0.88 KDM4E (0.39) SMN1; SMN2HTTLMNAPOLBTSHR
SCHEMBL3017841 0.87 POLB (0.42) SMN1; SMN2HTTPOLBTSHRKDM4E
SCHEMBL3018931 0.87 KDM4E (0.39) SMN1; SMN2HTTLMNAPOLBTSHR
SCHEMBL3019256 0.87 TSHR (0.39) SMN1; SMN2HTTLMNAPOLBTSHR
SCHEMBL3012800 0.87 KDM4E (0.40) SMN1; SMN2HTTLMNAPOLBTSHR
SCHEMBL3013654 0.87 DRD2 (0.39) SMN1; SMN2HTTLMNAPOLBTSHR
SCHEMBL3016935 0.86 L3MBTL1 (0.41) SMN1; SMN2HTTLMNATSHRRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885HTT 2/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.